Borosil Scientific Limited has informed the Exchange regarding 'Investor Presentation on Financial Results for the Quarter and Year ended March 31, 2026.
BOROSCI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Borosil Scientific Limited released its Q4FY26 and FY26 investor presentation. Consolidated Q4FY26 net sales grew 10.6% YoY to ₹143.2 crore, while EBITDA surged 87.6% YoY to ₹32.4 crore and PAT jumped 216.2% YoY to ₹27.2 crore, driven by higher sales and improved production efficiency. Full-year FY26 consolidated revenue was ₹467.3 crore (up 6.6% YoY), EBITDA was ₹64.7 crore (up 16.4% YoY), and PAT was ₹34.6 crore (up 29.4% YoY). Standalone EBITDA margin for FY26 expanded to 17.1% from 15.6% in FY25. The company holds a net cash position of ₹128.1 crore and operates across four segments: Laboratory Glassware & Consumables, Lab Equipment, Process Systems, and Pharmaceutical Primary Packaging. Management reiterated a medium-term target of 12–14% revenue CAGR with focus on high-margin Process Sciences and Lab Equipment segments.
Strong Q4FY26 and full-year FY26 results with sharp margin expansion and PAT growth signal operational efficiency gains. The company's net cash position and stated revenue CAGR target of 12–14% are positive for long-term shareholders, though near-term valuations may already reflect the rally.